- Home
- OTLK vs BNR Comparison
OTLK vs BNR Comparison
Compare OTLK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- BNR
- Stock Information
- Founded
- OTLK 2010
- BNR 2014
- Country
- OTLK United States
- BNR China
- Employees
- OTLK N/A
- BNR N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- BNR Medical Specialities
- Sector
- OTLK Health Care
- BNR Health Care
- Exchange
- OTLK Nasdaq
- BNR Nasdaq
- Market Cap
- OTLK 42.8M
- BNR 38.3M
- IPO Year
- OTLK 2016
- BNR 2020
- Fundamental
- Price
- OTLK $1.15
- BNR $9.02
- Analyst Decision
- OTLK Buy
- BNR
- Analyst Count
- OTLK 5
- BNR 0
- Target Price
- OTLK $5.25
- BNR N/A
- AVG Volume (30 Days)
- OTLK 2.7M
- BNR 24.9K
- Earning Date
- OTLK 08-14-2025
- BNR 09-08-2025
- Dividend Yield
- OTLK N/A
- BNR N/A
- EPS Growth
- OTLK N/A
- BNR N/A
- EPS
- OTLK N/A
- BNR N/A
- Revenue
- OTLK $1,505,322.00
- BNR $74,862,782.00
- Revenue This Year
- OTLK N/A
- BNR $136.32
- Revenue Next Year
- OTLK $343.94
- BNR N/A
- P/E Ratio
- OTLK N/A
- BNR N/A
- Revenue Growth
- OTLK N/A
- BNR 5.20
- 52 Week Low
- OTLK $0.79
- BNR $2.18
- 52 Week High
- OTLK $6.98
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- OTLK 46.22
- BNR 55.51
- Support Level
- OTLK $1.04
- BNR $8.91
- Resistance Level
- OTLK $1.13
- BNR $9.77
- Average True Range (ATR)
- OTLK 0.07
- BNR 0.54
- MACD
- OTLK 0.05
- BNR -0.04
- Stochastic Oscillator
- OTLK 84.91
- BNR 62.13
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.